CTx-1301 Comparative Bioavailability Study
A Randomized, Single-dose, Four-sequence, Four-period, Crossover Study in Adult ADHD Subjects to Establish Safety, Tolerability, and Comparative Bioavailability of CTx-1301 (Dexmethylphenidate) to Focalin XR™ Under Fasted Conditions
Sponsor: Cingulate Therapeutics
A PHASE1/PHASE2 clinical study on ADHD, this trial is completed. The trial is conducted by Cingulate Therapeutics and has accumulated 13 data snapshots since 2019. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
May 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Phase: PHASE1 → PHASE1_PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Completed PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Apr 2020 — Jul 2020 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cingulate Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .